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Abstract
Background: The aim was to investigate the reinfection rate of H. pylori during a follow-up period of 12 months in
adults who had undergone eradication therapy.
Methods: One hundred-twenty patients; 116 with gastritis, 3 with duodenal ulcer and 1 gastric ulcer, were studied.
Their mean age was 41 ± 13 years (range 18–77) and male: female ratio of 2:1. H. pylori were cultured and antibiotic
sensitivity was determined by Epsilometer test (E-test) for clarithromycin (CLR) and amoxicillin (AMX). Primers of urease
C gene of H. pylori and Sau-3 and Hha I restriction enzymes were used for polymerase chain reaction-restriction
fragment length polymorphism analysis (PCR-RFLP). 14C urea breath test (14C-UBT) was performed 4 weeks after the
eradication therapy. The successfully treated patients were observed for 12 months with 14C-UBT to assess H. pylori
status. If 14C-UBT was negative, it was repeated after every 12 weeks. If 14C-UBT was positive, endoscopy was repeated
with biopsies.
Result: The eradication therapy was successful in 102(85%) patients. Out of forty-seven H. pylori isolates cultured,
clarithromycin sensitivity was present in 30(64%) and amoxicillin in 45(98%), respectively. Follow-up 14C-urea breath
tests of all 102 patients who eradicated H. pylori remained negative up to 9 months. However, in 6 patients,
the 14C-UBT confirmed recurrence at 12 months. The recurrence rate was 6%.
Conclusion: A low rate of recurrence of H. pylori infection was found in patients with dyspeptic symptoms. H. pylori
isolates demonstrated a high invitro clarithromycin resistance.
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Background
Helicobacter pylori (H. pylori) is a Gram negative microorganism that has been categorized as a class I carcinogen
[1]. It is associated with gastritis, gastric and duodenal
ulcers, gastric adenocarcinoma, and mucosa-associated
lymphoid tissue lymphoma [2]. Long term chronic gastritis associated with H. pylori is known to progress to glandular atrophy and intestinal metaplasia (IM) over a period
of 12 years [3]. Helicobacter pylori gastritis may lead to
multifocal atrophy and IM, gradually expanding from the
antrum to the body [3]. A long term study with five year
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follow up from China have reported no change in the
degree of intestinal metaplasia (IM) and atrophy after
successful eradication [3]. In other long term randomized
controlled trials there was a significant regression of
preneoplastic lesions such as atrophy and IM among those
who had cleared the infection after five to six years of
follow up [4,5]. A definite cure of peptic ulcer disease and
prevention of ulcer complications, as well as cure of
mucosa-associated lymphoid tissue (MALT) lymphoma is
dependent on successful eradication of H. pylori.
Recurrence of H. pylori after a successful eradication is
rare in developed countries and more frequent in developing countries [6]. Recrudescence is recolonization of
the same strain while reinfection is colonization with a
new strain. Reinfection is considered to be more likely
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to be responsible for most of the cases [6]. This differentiation is difficult and requires utilization of molecular
fingerprinting techniques to confirm that the identified
bacteria, before and after therapy, are genetically identical [7]. Recrudescence results from treatment failure
while reinfection is considered a problem of heavy H.
pylori contamination of the environment, drinking water,
institutionalized patients, medical personnel or family
members, especially in developing countries [6]. In developing countries, H. pylori infection is widespread.
Regional studies available from Bangladesh, India and
Iran have shown varied recurrence rates [8-10]. In a recent
study in Karachi in apparently healthy children, H. pylori
seroprevalence in children aged 11–15 years was 54% [11].
H. pylori seropositivity increased with age and in lowmiddle socioeconomic status [11]. However, local studies
addressing the issue of recurrence of H. pylori are not
available. In this study we investigated the recurrence rate
of H. pylori during a follow-up period of 12 months in
adults who had undergone eradication therapy.

Table 1 Patients characteristics

Sensitive

30(64)

Methods

Resistance

17(36)

Patients

Amoxicillin

One hundred-twenty consecutive patients with dyspepsia attending the endoscopy suite of gastroenterology
section of Aga Khan University Hospital were enrolled
from April 2008–June 2010. There were eighty males
and forty females (age range 17–80 years, mean age 41
± 13 years; Table 1). An informed consent was taken
from all patients and the Aga Khan University ethics review committee approved the study. Only those who
were willing to comply with the follow-up schedule and
gave informed consent were enrolled in the study. Pregnant and lactating women, patients with esophageal or
gastric tumors and patients with liver cirrhosis and
esophageal varices were excluded. In addition, those who
had received antisecretory drugs, antibiotics, nonsteroidal anti-inflammatory drugs, corticosteroids or bismuthcontaining drugs during the preceding 8 weeks were
also excluded. All the patients were native residents of
the city. Endoscopic examination was conducted using
Olympus video endoscopes (Olympus Tokyo, Japan),
and the presence of lesions in the esophageal and gastroduodenal mucosa was noted. Gastric biopsy specimens
were obtained three each from the antrum and corpus
for rapid urease test (RUT), histology, culture and PCR
for H. pylori urease C gene. The biopsies from the antrum were obtained 2–3 cm from the pylorus, and from
the body, midway between the antral-body junction and
the cardia. Patients who were positive for H. pylori infection by means of 14C-UBT with RUT or histology received treatment comprising of a proton pump inhibitor
(esomeprazole) 20 mg BD (twice a day) for 10 days and
clarithromycin 500 mg BD and amoxicillin 500 mg BD

Sensitive

Age (years)
Mean ± SD
Range

41 ± 13
18-77

Gender
Male

80(67)*

Female

40(33)

Diagnosis
Gastritis

116(97)

Gastric ulcer

1(1)

Duodenal ulcer

3(2)

Histology
Grade 1

61(51)

Grade 2

54(45)

Grade 3

5(4)

Antibiotic susceptibility pattern

n = 47

Clarithromycin

Resistance

45(96)
2(4)

H. pylori DNA fingerprint (PCR-RFLP)
Same on both sides

102(85)

Different on both sides

18(15)

*n (%) = number and percentage.

for 7 days. Two weeks after completion of treatment,
14
C-UBT was performed to document eradication of H.
pylori infection. Patients with positive 14C-UBT were
excluded from the study while those with negative were
followed up every 3 months by a 14C-UBT for 12 months
until it tested positive and was followed by endoscopy
and biopsy.
Sample size

The required sample size is 103 individuals, calculated
on the basis of an estimated prevalence of reinfection of
13% and bound on error of estimation specified to be at
the most .065 (6.5%) and a confidence level of 95% [8].
Rapid urease test

The tissue specimens were used for the RUT (Pronto
dry, Medical Instrument Corp, France) consisting of a
dry filter paper enriched with urea, phenol red (a pH indicator), buffers and a bacteriostatic agent in a sealed
plastic slide [12]. H. pylori urease enzyme present in the
biopsy tissue sample decomposed urea to cause a pH
rise that changed color of the dot from yellow to a bright
magenta. Pronto Dry results were read in 30 minutes
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and one hour. The color change from yellow to pink
was considered a positive result and no color change as
negative for Pronto Dry.
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urease positive. H. pylori NCTC 11637 (type strain) was
used as a positive control for the culture conditions and
identification tests.

Histological analysis

Formalin-fixed and paraffin-embedded gastric biopsy
specimens were routinely processed. Gastritis activity
was graded on a four-point scale of none (grade 0), mild
(grade 1), moderate (grade 2), and severe (grade 3)
according to the guidelines of the Sydney system [13].
The presence of H. pylori was assessed on modified
Giemsa-stained sections.
C- Urea breath test

14

Patients swallowed 37 kBq (1 μCi) of an encapsulated
form of 14C-urea/citric acid composition (Helicap, Noster
System AB, Sweden) with water after endoscopy [14].
Breath samples were collected with a special dry cartridge
system (Heliprobe Breath Card, Noster System AB,
Sweden) after 10 min. Patients exhaled gently into the
cartridge mouthpiece until the indicator membrane
changed in color from orange to yellow. Breath card was
inserted into a β-scintillation counter (Heliprobe-analyser,
Noster System AB Stockholm, Sweden) and activity was
counted for 250 s. Results were expressed both as counts
per minute (HCPM) and as grade (0: not infected, CPM <
25; 1: equivocal, CPM 25–50; 2: infected, CPM > 50),
which was suggested by the manufacturer according to
the counts obtained from the cartridges. Grades 0 and 1
were considered negative for the detection of H. pylori. In
a previous study the accuracy of 14C-UBT was compared
to histology and RUT. Accuracy of 14C-UBT was 93% in
comparison with histology while its positive and negative
predictive values were 97% and 84%, respectively [14].
Comparison of 14C-UBT with RUT gives an accuracy of
96%, with positive and negative predictive values of 95%
and 97%, respectively [14].
Culture and identification of H. pylori

The specimens were transported immediately in sterile
phosphate buffered saline to isolate H. pylori. Thus,
within three hours of collection each specimen was homogenized and the resulting suspension was inoculated
onto Columbia Blood Agar (Oxoid) medium and Dents
supplement (containing vancomycin, trimethoprim and
polymyxin) and incubated at 37°C under microaerophilic
conditions for 4–7 days. Plates were then examined for
bacterial growth and typical colonies were selected for
identification. The identity of H. pylori was confirmed by
Gram stain, urease and catalase test. One half of the
homogenate was used for culture, and the other half was
kept at −80°C for future DNA extraction. H. pylori isolates were defined as gram-negative spiral-shaped bacilli
that were catalase positive and rapidly (less than 1 h)

Antibiotic susceptibility testing

Antibiotic susceptibility was determined on Mueller Hinton
agar (Oxoid, UK) containing 10% defibrinated sheep blood
and a cell suspension calibrated at 3 McFarland units by
the Epsilometer (E-test) using clarithromycin and amoxicillin E-test strips (AB Biodisk, Solna, Sweden). Plates were
read after 3 days of incubation at 37°C. The tests were
carried out according to the manufacturer’s instructions.
H. pylori NCTC 11637 was used as a sensitive control.

Extraction of genomic DNA

DNA was extracted from gastric tissue as described
before [15]. Samples were stored at −20°C before PCR
amplification was performed. DNA content and purity
was determined by measuring the absorbance at 260 nm
and 280 nm using a spectrophotometer (Beckman DU600, USA).

PCR amplification for H. pylori ure C gene

PCR was performed using extracted DNA as the template and urease gene C for primers. Forward primer (5’TGGGACTGATGGCGTGAGGG-3’) and reverse primer
(5’-AAGGGCGTTTTTAGATTTTT-3’) were prepared
from the urease gene sequence according to the report
of Labigne et al. [16]. PCR amplification was carried out
in a total volume of 50 μL containing 2 μL of 2 mmol/L
dNTPs, 1 μL containing 50 ρmol of primer 1, 1 μL
containing 50 ρmol of primer 2 (synthesized by ABI
Automatic synthesizer), 1 unit of Taq DNA polymerase
(Promega), 5 μL of 10 × PCR reaction buffer, 3 mmol/L
of MgCl2, 2 μL of DNA template containing 0.5 ng of
extracted DNA and total volume rounded to 50 μL by
double distilled water. The reaction was carried out in a
Perkin Elmer 9700 thermal cycler. The amplification
cycle consisted of an initial denaturation of target DNA
at 95°C for 5 min and then denaturation at 94°C for
1 min, primer annealing at 56°C for 1 min and extension
at 72°C for 1 min. The final cycle included an extension
step for 5 min at 72°C to ensure full extension of the
product. Samples were amplified through 35 consecutive
cycles. Negative reagent control reactions were performed
with each batch of amplifications, consisting of tubes
containing distilled water in place of the DNA samples.
Five μL of PCR product was electrophoresed on a 1.5%
agarose gel to ensure homogeneity and yield. PCR amplification resulted in a homogeneous DNA fragment of the
expected size of 820 bp for ure C gene.
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PCR-RFLP

The amplified products obtained by PCR were subjected
to restriction endonuclease digestion for 2 hours at 37°C
in 20 microliter (μl) volume, as recommended [17]. The
digested samples were analyzed by agarose gel (3%, wt/
volume) electrophoresis. Restriction enzyme Sau-3 (5U)
and Hha I (5 U), (New England Biolabs) were used on
the basis of sequence data available for this amplified
product. The restriction enzyme HhaI recognized on the
820-bp UreC gene amplified PCR product restriction site
5’. . .GCG↓ C . . .3’ giving 2 fragments varying in size
from 100 bps to 550 bps and showing 4 band patterns
while restriction enzyme Sau3A1 recognized site 5’. . .↓
GATC..3’giving 3 fragments ranging in size from 50 bps
to 600 bps having 7 bands patterns, respectively. RFLP
analysis by HhaI and Sau 3A together generated eleven distinguishable digestion patterns. Small variations (<10 bps)
in the size of the restriction fragments were not considered
a different pattern. In case of an identical restriction
pattern from antrum and body, the patient was considered
to have an infection by the same H. pylori strain while by
restriction fragments that exceeded amplified fragment size
and yielded different restriction fragments, patient was
considered to be infected by different H. pylori strains.
Statistical assessment

The statistical package for social science SPSS (Release
16, standard version, copyright © SPSS; 1989–2007) was
used for data analysis. The descriptive analysis was done
for demographic and clinical features. Results were
presented as mean ± standard deviation for quantitative
variables and number (percentage) for qualitative variables. Differences in proportion were assessed by using
Pearson Chi square, Fisher exact or likelihood ratio test
where appropriate. P value less than 0.05 was considered
as statistically significant, all p values were two sided.

Results
All one hundred-twenty patients with H. pylori infection
had positive 14C-UBT. Rapid urease test was positive in
116 out of 120 (97%) and negative in 4 out of 120 (3%).
Histology demonstrated H. pylori associated gastritis in
114 out of 120 (95%) and nonspecific gastritis in 6(5%).

Four patients negative by RUT had positive C-14 UBT
and H. pylori positive gastritis while six patients demonstrating nonspecific gastritis had positive 14C-UBT and
RUT. The distribution of negative RUT (p = 1 and p =
0.69) and histology (p = 0.600 and p = 0.095) for H. pylori
infection were not associated with age and gender.
Recurrence of H. pylori after successful eradication

One hundred-twenty patients had positive 14C-UBTs on
initial visit. After treatment 18 out of 120 (15%) were still
positive and were excluded from the study. At 12 months,
the 14C-UBT confirmed recurrence in six patients. No statistically significant difference was seen for sex (Fisher’s
Exact Test p = 1) or age (p =0.697). All cases of recurrence
were from the local population. They were diagnosed as
having non-ulcer dyspepsia (NUD) with evidence of endoscopic gastritis and mild to moderate chronic active gastritis on histology (Table 2). In the follow-up period, none of
the 3(3%) duodenal ulcer patients with successful eradication had any symptoms suggesting ulcer though we did
not do repeat endoscopy in these patients.
PCR-based RFLP analysis

In 103 of 120 isolates (86%), we demonstrated the same
DNA fingerprint from isolates from the antrum and
mid-body gastric sites, and the patterns were different in
17(14%). Six of the 102 patients had recurrence of H.
pylori during the follow-up period after treatment. Five
of these 6 patients were previously documented to have
colonization by multiple H. pylori isolates while in one
patient a single H. pylori isolate was present on antrum
and corpus. Following recurrence, 4 out of 6 patients
had colonization by multiple H. pylori isolates and 2 single H. pylori isolate on antrum and body.
Antibiotic susceptibility of H. pylori isolates

Forty-seven H. pylori isolates were cultured from pretreatment biopsies. H. pylori culture was negative from
both antrum and corpus in patient having a positive
14
C-UBT at 12 month and follow up endoscopic with biopsies. Clarithromycin sensitivity was present in 30 out
of 47 (64%) and amoxicillin in 45 out of 47 (98%), respectively (Table 2).

Table 2 Comparison of histology with diagnosis, bacterial colonization and antibiotic susceptibility
H. pylori DNA fingerprint

Diagnosis

Clarithromycin

Gastritis

Gastric Ulcer

Duodenal ulcer

Same on
both sides

Different on
both sides

Sensitive

Resistant

Grade 1

60(52)

0(0)

1(33)

48(47)

13(72)

12(40)

Grade 2

51(44)

1(100)

2(67)

49(48)

5(28)

Grade 3

5(4)

0(0)

0(0)

5(5)

0(0)

Amoxicillin
P

Sensitive

Resistant

11(65)

22(49)

1(50)

18(60)

5(29)

22(49)

1(50)

0(0)

1(6)

1(2)

0(0)

Histology

*n (%) = number and percentage.
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Comparison of antibiotic susceptibility and H. pylori DNA
fingerprint at gastric site

H. pylori DNA fingerprints were different in antrum and
corpus in 3(10%) out of 30 CLR sensitive strains compared to 10(59%) out of 17 CLR resistance H. pylori
strains (p = 0.001).
By RFLP 18 patients had different DNA fingerprints in
the antrum and corpus (Table 2). Of these 18 patients,
H. pylori could be cultured from only 13 patients.
Clarithromycin resistance was demonstrated by 10 out
of 13 H. pylori isolates while 3 out of 13 were sensitive
to CLR.
Comparison of histology with diagnosis and antibiotic
susceptibility

The degree of gastric inflammation in majority of patients
varied from grade 1 to 2 (Table 2). It was not significantly
associated with diagnosis (p = 0.66) (Table 2). Grades of
inflammation were equally associated with same or different H. pylori DNA fingerprints in antrum and corpus
(p = 0.08) (Table 2). Eleven out of 17 (65%) H. pylori
strains demonstrating CLR resistance were associated with
grade 1 inflammation (p = 0.06) while grade 1 to 2 inflammation were equally associated with AMX resistance (p =
0.957), respectively (Table 2).

Discussion and conclusion
The results of this prospective study showed that rate of
H. pylori recurrence after apparently successful eradication was low. Majority of our patients remained infection free at nine months and recurrence followed in
about 6% at the end of one year. All the patients with recurrence had NUD while none occurred in cases with
duodenal ulcer. Clarithromycin resistance was high in
our H. pylori isolates and low for amoxicillin. Antibiotic
susceptibility pattern was not found to be related to age
and gender in this study. About 14% of our patients
demonstrated colonization by multiple H. pylori strains.
Clarithromycin resistance was associated with different
H. pylori strains at different gastric sites as suggested by
DNA fingerprinting. However, the technique used in this
study looked at only one gene, and generated as few as 2
or 3 bands in some strains, making it a rather low resolution technique to declare a strain identical. Strains
may show identical banding patterns in the RFLP sites in
one gene, yet differ elsewhere. Furthermore, it is possible
that in some subjects, the infection was eradicated, yet
the subject was reinfected from family members with an
identical or near-identical strain, which would be
interpreted as recrudescence.
Most studies from developed countries reported less
than 1% rate of H. pylori infection recurrence whereas
relatively higher rates have been reported from developing countries [18]. True re-infection of H. pylori is
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defined as where tests for H. pylori infection stay negative for 12 months after eradication, and become positive
again at a later stage. This is probably a rare event in developed countries. A study from the Netherlands [19]
showed that at 6 years after successful triple therapy the
recurrence rate of H. pylori infection was very low
(0.19% per patient year). Recurrence rate is higher in
developing countries. In a study from Bangladesh, recrudescence, associated with nitroimidazole-based treatment, occurred in 15 of 105 patients (13%) within the
first 3 months while the annual reinfection rate was
13%, based on a total follow-up of 84.7 patient years [8].
Data from India on reinfection of H. pylori after eradication showed that the risk is low in Indian subjects at the
end of one year. The eradication rate with the four-drug
regimen was 89.1% (41/46). Four of the 5 nonresponders eradicated H. pylori with the second regimen.
At the end of median one year follow-up (range 9–15 months), one of the 45 patients (2.4%) who eradicated
the organism developed reinfection; none of the 46 patients who were initially H. pylori-negative acquired new
infection [9]. In Iran, 37 patients, aged 5 to 17 years,
treated with triple omeprazole based regimen the reinfection rate of H. pylori was determined during a follow up period of 12 months. After eradication therapy of
H. pylori, 34 patients had a negative repeat 13C-UBT.
Reinfection occurred in 5 (14.7%) patients [10].
The recurrence rate of 6% in our study is similar to
that reported from Chile and China (4.2% /yr. and 1.08%
/yr., respectively) [20,21]. It is, however, less than that
reported in Korea (13%) [22] and Bangladesh (13%). This
discrepancy might be explained by the fact that criteria
to define eradication of infection, number of patients
studied, and time of follow-up varied from one study to
another [8,20-22]. Increased susceptibility of hosts to H.
pylori infection and re-exposure to H. pylori are proposed to be the major requirements for re-infection of
H. pylori [23,24]. Poor sanitation practices in the developing countries result in contamination of the environment with H. pylori, such as in drinking water, practice
of eating uncooked vegetables; crowded living conditions
thatl contribute to re-exposure to H. pylori infection and
result in high prevalence of H. pylori infection [25-27].
Genetic factors may also play a role in re-infection of H.
pylori infection after successful eradication. Susceptible
individuals who have had H. pylori eradicated may be
prone to re-infection with the bacterium when they are exposed to H. pylori-positive persons [28]. Self-prescription is
also common in developing countries as medications are
sold without prescriptions by pharmacies [29]. Most reports on antimicrobial therapy of H.pylori propose that
antibiotic overuse selects for resistant strains as they eradicate the susceptible H. pylori population, and resistant survivors replace them as a resistant majority [30-33]. The
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resistance trait could be spread horizontally by plasmids
to other bacterial population. Emergence of a resistance
phenotype is a short-term phenomenon that takes 4 – 5 years to emerge and the driving force is the indiscriminate,
short-interval and frequent use of antibiotics [33-35].
Clarithromycin resistance rate was high in H. pylori isolates
probably contributed to by use of this drug for other indications in the community and this might result in selection
of stable macrolide-resistant H.pylori and indigenous
microbiota [36]. Also, previously a low cure rate and a
higher resistance to clarithromycin were observed among
H. pylori positive patients with functional dyspepsia than
that in peptic ulcer disease [37-39]. In an earlier study, we
reported treatment failure was associated with younger
mean age, cagA negativity and point mutations in 23S
rRNA gene of H. pylori [40]. In conclusion, in spite of having a high prevalence of H. pylori there is a low incidence
of recurrence of H. pylori infection in our population once
eradication has been achieved. In view of high CLR resistance, judicious use of antibiotics should follow in general.
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